A total of 2489 early-stage breast cancer patients from 32 centers (Supplementary Fig. S1) who underwent neoadjuvant chemotherapy were included: 450 patients with HER2-0 tumors, 1023 with HER2-low tumors, and 1016 with HER2-positive tumors (Fig. 1). Here, ERBB2 is linked to breast cancer.